Date:2021/6/15	
Your Name: Fei Gao	
Manuscript Title:_ Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor prote	ein
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	VNone			
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	VNone			
3	Royalties or licenses	√None			
4	Consulting fees	vNone			

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	√NoneVNone
7	Support for attending meetings and/or travel	VNone
8	Patents planned, issued or pending	VNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	VNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None
11	Stock or stock options	√None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√None
13	Other financial or non- financial interests	√None

Dr. Gao has nothing to disclose.

# Please place an "X" next to the following statement to indicate your agreement:

Date:2021/	6/15
Your Name:	Dingving Wu

Manuscript Title:\_ Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initial	planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	VNone			
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	VNone			
3	Royalties or licenses	√None			
4	Consulting fees	√None			

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	VNone
7	Support for attending meetings and/or travel	√None
8	Patents planned, issued or pending	VNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	vNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None
11	Stock or stock options	√None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√None
13	Other financial or non- financial interests	√None

Dr. Wu has nothing to disclose.

# Please place an "X" next to the following statement to indicate your agreement:

Date:2021/	5/15
Your Name:	Lingling Guo

Manuscript Title:\_ Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	VNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	VNone   VNone   VNone
7	Support for attending meetings and/or travel	VNone
8	Patents planned, issued or pending	vNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	VNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None
11	Stock or stock options	√None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√None
13	Other financial or non- financial interests	√None

Dr. Guo has nothing to disclose.

# Please place an "X" next to the following statement to indicate your agreement:

Date:\_\_2021/6/15\_\_\_\_\_

Your Name:\_\_\_ Lixue Wang \_\_\_

Manuscript Title:\_ Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein Manuscript number (if known):\_\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	VNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	√None	
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	√NoneVNone
7	Support for attending meetings and/or travel	VNone
8	Patents planned, issued or pending	VNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	VNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None
11	Stock or stock options	√None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√None
13	Other financial or non- financial interests	√None

Dr. Wang has nothing to disclose.

# Please place an "X" next to the following statement to indicate your agreement:

Date:2021/6/15	
Your Name: Min Hao	
Manuscript Title:_ Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein	n
Manuscript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	VNone	
2	Grants or contracts from	Time frame: past	36 months
Z	any entity (if not indicated in item #1 above).	VNone	
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	√NoneVNone
7	Support for attending meetings and/or travel	VNone
8	Patents planned, issued or pending	VNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	VNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None
11	Stock or stock options	√None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√None
13	Other financial or non- financial interests	√None

Dr. Hao has nothing to disclose.

# Please place an "X" next to the following statement to indicate your agreement:

Date:2021/6/15
Your Name: Ling Li
Manuscript Title:_ Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	VNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	VNone	
3	Royalties or licenses	√None	
4	Consulting fees	vNone	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	√NoneVNone
7	Support for attending meetings and/or travel	VNone
8	Patents planned, issued or pending	VNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	VNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None
11	Stock or stock options	√None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√None
13	Other financial or non- financial interests	√None

Dr. Li has nothing to disclose.

# Please place an "X" next to the following statement to indicate your agreement:

Date:2021/6/15
Your Name: Dongmei Ni
Manuscript Title:_ Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	VNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	VNone	
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	VNone   VNone   VNone
7	Support for attending meetings and/or travel	VNone
8	Patents planned, issued or pending	vNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	VNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None
11	Stock or stock options	√None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√None
13	Other financial or non- financial interests	√None

Dr. Ni has nothing to disclose.

# Please place an "X" next to the following statement to indicate your agreement:

Date:2021/6/15			
Your Name: Haojie Hao			
Manuscript Title:_ Liraglutide inhibits the progression of prediabetes in rats by reducing Raf-1 kinase inhibitor protein			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	VNone	
2	Grants or contracts from	Time frame: past	36 months
Z	any entity (if not indicated in item #1 above).	VNone	
3	Royalties or licenses	√None	
4	Consulting fees	√None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony	√None  √None	
7	Support for attending meetings and/or travel	VNone	
8	Patents planned, issued or pending	√None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	√None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	√None	
11	Stock or stock options	√None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	√None	
13	Other financial or non- financial interests	Beijing Hengfeng Mingcheng Biotechnology Co., Ltd	

Dr. Hao is from Beijing Hengfeng Mingcheng Biotechnology Co., Ltd. This study had no fund or agents from this company.

# Please place an "X" next to the following statement to indicate your agreement: